External Beam Radiation Therapy (EBRT) With or Without Hormonal Therapy in Prostate Cancer
Summary
Primary Objective: * To assess the possible improvement in prostate specific antigen (PSA) outcome of short course androgen suppression therapy in conjunction with dose-escalation intensity modulated radiation therapy (IMRT), 3D conformal radiation therapy (3D-CRT), or proton therapy over IMRT, 3D-CRT, or proton therapy alone in prostate cancer patients traditionally considered at intermediate risk for PSA failure following conventional local therapy. PSA failure will be the primary endpoint. Secondary Objectives: * To assess local control, freedom from distant metastasis, and overall survival. * To study the impact of radiation therapy and/or hormone therapy on health-related quality of life measures using the Expanded Prostate Cancer Index Composite-Short Form 12-American Urological Association Symptom Index (EPIC-SF12-AUASI: http://roadrunner.cancer.med.umich.edu/epic/). * To assess prognostic value of pretreatment serum testosterone as well as the decrease in hemoglobin from neoadjuvant hormone therapy. * To assess prognostic value of pretreatment biomarkers on subsequent post-treatment clinical outcomes.
Timeline
- Start
- 2005-02
- Primary completion
- 2011-04
- Completion
- 2011-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Bicalutamide | Other / unclassified | 50 mg | Oral |
| Comparator | Goserelin | Other / unclassified | 3.6 mg | Subcutaneous |
| Comparator | Goserelin | Other / unclassified | 10.8 mg | Subcutaneous |
| Comparator | Leuprolide | Other / unclassified | 7.5 mg | Intramuscular |
| Comparator | Leuprolide | Other / unclassified | 22.5 mg | Intramuscular |
| Comparator | flutamide | Small molecule | 250 mg | Oral |